Logo image of ONC.CA

ONCOLYTICS BIOTECH INC (ONC.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:ONC - CA6823108759 - Common Stock

1.42 CAD
+0.03 (+2.16%)
Last: 8/22/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ONC. ONC was compared to 22 industry peers in the Biotechnology industry. The financial health of ONC is average, but there are quite some concerns on its profitability. ONC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ONC has reported negative net income.
ONC had a negative operating cash flow in the past year.
In the past 5 years ONC always reported negative net income.
In the past 5 years ONC always reported negative operating cash flow.
ONC.CA Yearly Net Income VS EBIT VS OCF VS FCFONC.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ONC has a Return On Assets (-152.26%) which is in line with its industry peers.
ONC has a Return On Equity (-499.46%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ONC.CA Yearly ROA, ROE, ROICONC.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONC.CA Yearly Profit, Operating, Gross MarginsONC.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for ONC has been increased compared to 1 year ago.
Compared to 5 years ago, ONC has more shares outstanding
ONC has a worse debt/assets ratio than last year.
ONC.CA Yearly Shares OutstandingONC.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ONC.CA Yearly Total Debt VS Total AssetsONC.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -33.32, we must say that ONC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ONC (-33.32) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.10 indicates that ONC is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.10, ONC is doing good in the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -33.32
ROIC/WACCN/A
WACCN/A
ONC.CA Yearly LT Debt VS Equity VS FCFONC.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

ONC has a Current Ratio of 2.88. This indicates that ONC is financially healthy and has no problem in meeting its short term obligations.
ONC has a Current ratio of 2.88. This is in the better half of the industry: ONC outperforms 66.67% of its industry peers.
A Quick Ratio of 2.88 indicates that ONC has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.88, ONC is doing good in the industry, outperforming 70.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
ONC.CA Yearly Current Assets VS Current LiabilitesONC.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

ONC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.63%.
EPS 1Y (TTM)2.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 25.19% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y25.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONC.CA Yearly Revenue VS EstimatesONC.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ONC.CA Yearly EPS VS EstimatesONC.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONC.CA Price Earnings VS Forward Price EarningsONC.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONC.CA Per share dataONC.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3Y10.11%

More info and screens

0

5. Dividend

5.1 Amount

ONC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLYTICS BIOTECH INC

TSX:ONC (8/22/2025, 7:00:00 PM)

1.42

+0.03 (+2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners1.52%
Inst Owner ChangeN/A
Ins Owners4.01%
Ins Owner ChangeN/A
Market Cap126.12M
Revenue(TTM)N/A
Net Income(TTM)-30.41M
Analysts77.5
Price Target4.6 (223.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)20.79%
Max EPS beat(2)35.03%
EPS beat(4)3
Avg EPS beat(4)14.8%
Min EPS beat(4)-15.35%
Max EPS beat(4)35.03%
EPS beat(8)6
Avg EPS beat(8)14.12%
EPS beat(12)8
Avg EPS beat(12)8.97%
EPS beat(16)11
Avg EPS beat(16)10.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.58%
PT rev (3m)0.24%
EPS NQ rev (1m)9.37%
EPS NQ rev (3m)12.12%
EPS NY rev (1m)20.83%
EPS NY rev (3m)20.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 20.71
P/tB 20.71
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -152.26%
ROE -499.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -33.32
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.58%
Cap/Depr(5y)28.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y21.99%
EPS Next 2Y6.67%
EPS Next 3Y10.11%
EPS Next 5Y25.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.16%
EBIT Next 3Y5.76%
EBIT Next 5Y42.82%
FCF growth 1Y6.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.92%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLYTICS BIOTECH INC / ONC.CA FAQ

What is the ChartMill fundamental rating of ONCOLYTICS BIOTECH INC (ONC.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ONC.CA.


What is the valuation status for ONC stock?

ChartMill assigns a valuation rating of 0 / 10 to ONCOLYTICS BIOTECH INC (ONC.CA). This can be considered as Overvalued.


How profitable is ONCOLYTICS BIOTECH INC (ONC.CA) stock?

ONCOLYTICS BIOTECH INC (ONC.CA) has a profitability rating of 1 / 10.